SynthesisMedicine2026
Genetic evidence for associations between gastroesophageal reflux disease and site-specific extraesophageal cancers: A Mendelian randomization study.
Synthesis in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Observational studies have suggested an increased risk of extraesophageal cancers in patients with gastroesophageal reflux disease (GERD), but whether these associations are causal remains uncertain. This study systematically evaluated the potential associations between genetically predicted GERD and 22 extraesophageal cancers. Genetic instruments for GERD were obtained from a large genome-wide association study including 129,080 cases and 473,524 controls. Outcome data for 22 site-specific extraesophageal cancers were obtained from multiple genome-wide association study datasets, including the UK Biobank, FinnGen, and international cancer consortia. Two-sample Mendelian randomization (MR) analyses were performed, and dataset-specific MR estimates were subsequently combined using meta-analysis. For positive findings, reverse MR and Multivariable Mendelian randomization analyses were further conducted to assess causal direction and independence from body mass index, smoking intensity, and alcohol consumption. Meta-analysis of two-sample MR showed Bonferroni-significant positive associations of genetically predicted GERD with lung cancer (odds ratio [OR] = 1.220; 95% confidence interval [CI]: 1.100-1.354; P = .0002) and pancreatic cancer (OR = 1.517; 95% CI: 1.214-1.895; P = .0002). Suggestive positive associations were also observed for laryngeal cancer (OR = 1.774; 95% CI: 1.091-2.884; P = .021) and bladder cancer (OR = 1.254; 95% CI: 1.047-1.501; P = .014), although neither survived Bonferroni correction. In Multivariable Mendelian randomization analyses accounting for body mass index, smoking intensity, and alcohol consumption, the association with lung cancer remained statistically significant (OR = 1.190; 95% CI: 1.040-1.362; P = .012), whereas the associations with pancreatic, laryngeal, and bladder cancers were no longer statistically significant. These findings provide genetic evidence supporting an association between genetically predicted GERD and lung cancer. The evidence for pancreatic, laryngeal, and bladder cancers was less robust and requires further validation in larger independent datasets. These findings may help prioritize future research on cancer risk among individuals with GERD, with further studies warranted to validate the observed associations and clarify their underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.